Strong 1H18 Result and New Products Expected to Support Future Growth
CSL Ltd (CSL AU) reported their 1H18 result on 14 February 2018: Revenue $4,147m, up 11% at constant currency (cc) EBIT $1,476m, up 31% cc NPAT...
217 Views
Sanofi: Stop the Bleeding with Bioverativ
Today, Sanofi (SAN FP) announced that it is acquiring Bioverativ Inc (BIVV US) for $11.6 billion (a 64% premium). Management hosted a conference...
413 Views
CSL's Largest-Ever Clinical Trial for Recurrent Heart Attacks: High Unmet Medical Need
Blood product giant CSL Ltd (CSL AU) announced during its annual research & development briefing this morning that it will proceed with a Phase...
279 Views
Not All Players Are Equal in the Plasma Industry
According to Allied Market Research, the IVIG (intravenous IG) market was valued at US$7.86bn and is expected to reach US$12.36bn by 2022. IVIG is...
483 Views
China's Healthcare Reform Consolidates Drug Distribution and Cuts Manufacturer Margins
Rolling Out A âTwo Invoicesâ System Nationwide:Although the announcement of a new policy to consolidate the distribution channels for both...
368 Views